Plain-English translation of NCT04794777 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study compares two treatment approaches for men whose prostate cancer has come back after surgery. One group receives a specialized PET scan (using 68Ga-PSMA-11 or 18F-PSMA-1007) that can detect cancer cells in the body, and their treatment is customized based on those scan results. The other group receives standard radiation therapy without knowing what the new scan shows. Researchers want to find out if the new scanning method helps more patients achieve better long-term outcomes.
Currently, standard radiation therapy for recurrent prostate cancer only works well in about half of patients, and many still develop cancer again. The problem is that doctors may miss hidden cancer spots that have already spread to distant parts of the body or lymph nodes. This new scan is better at finding those hidden spots early, which could lead to more effective and personalized treatment plans.
You likely qualify if…
You likely don't qualify if…
You will have a specialized PET scan to look for any cancer that may have spread in your body. Depending on which group you are randomly assigned to, you will either receive treatment based on your scan results, or you will receive standard radiation therapy (your scan results will be kept hidden from your treatment team). Throughout the study, you will have regular PSA blood tests and complete quality-of-life questionnaires to track how you are doing. Follow-up visits and testing will continue for several years.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Sweden